Your browser doesn't support javascript.
loading
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL.
Nägele, Virginie; Kratzer, Andrea; Zugmaier, Gerhard; Holland, Chris; Hijazi, Youssef; Topp, Max S; Gökbuget, Nicola; Baeuerle, Patrick A; Kufer, Peter; Wolf, Andreas; Klinger, Matthias.
Afiliação
  • Nägele V; Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich, Germany.
  • Kratzer A; Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich, Germany.
  • Zugmaier G; Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich, Germany.
  • Holland C; Amgen Inc., Rockville, MD USA.
  • Hijazi Y; Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich, Germany.
  • Topp MS; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
  • Gökbuget N; Department of Medicine II, Goethe University, Frankfurt, Germany.
  • Baeuerle PA; Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich, Germany.
  • Kufer P; Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich, Germany.
  • Wolf A; Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich, Germany.
  • Klinger M; Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich, Germany.
Exp Hematol Oncol ; 6: 14, 2017.
Article em En | MEDLINE | ID: mdl-28533941
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article